Masahiro Tsuboi, MD

Articles by Masahiro Tsuboi, MD

Phase 3 ADAURA Study Highlights Role for Precision Medicine in EGFR-Positive NSCLC

January 5th 2021

Masahiro Tsuboi, MD, discusses the findings from the phase 3 ADAURA clinical trial of osimertinib as treatment of patients with EGFR-mutated non–small cell lung cancer.

Osimertinib Plays a Role for Patients With EGFR-Mutant NSCLC

ByMasahiro Tsuboi, MD

December 4th 2020

Masahiro Tsuboi, MD, discusses treatment with osimertinib for patients with EGFR-mutated non–small cell lung cancer and central nervous system disease recurrence.

ADAURA Study Demonstrates Promising Efficacy for Osimertinib in EGFR-Mutant NSCLC

ByMasahiro Tsuboi, MD

October 19th 2020

Masahiro Tsuboi, MD, discusses the key takeaways from the findings for osimertinib in patients with early-stage EGFR-mutant non–small cell lung cancer following a complete tumor resection in the phase 3 ADAURA clinical trial.

Masahiro Tsuboi, MD

Articles by Masahiro Tsuboi, MD

Phase 3 ADAURA Study Highlights Role for Precision Medicine in EGFR-Positive NSCLC

Osimertinib Plays a Role for Patients With EGFR-Mutant NSCLC

ADAURA Study Demonstrates Promising Efficacy for Osimertinib in EGFR-Mutant NSCLC

Latest Updated Articles

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL

Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC

Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma

Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma

LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors